US FDA Should Explain How It Uses Patient Experience Data In Drug Approvals – Report
Review documents do not always reflect whether PED was considered as part of an application, and stakeholders cannot easily determine how such data are used in the agency’s regulatory decision-making, an independent consultant review found.
You may also be interested in...
Sponsor concerns about commercial confidential information may be a sticking point in getting patient groups the desired data on when and how the FDA uses patient input in regulatory decision making.
Meetings are now primarily hosted by external patient advocacy groups, with accelerated approval and surrogate endpoints making their way into discussions. Stakeholders want more transparency on how FDA uses PFDD reports, and one agency staffer suggests adding other types of expertise to the meetings.
Final FDA guidance also suggests sponsors recruit representative populations and limit exclusions.